Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?

被引：1
|
作者：
Rizzo, Alessandro [1 ]
Palmiotti, Gennaro [1 ]
机构：
[1] IRCCS Ist Tumori Giovanni Paolo II, Struttura Semplice Dipartimentale Oncol Med, Presa Carico Globale Paziente Oncol Don Toni, Viale Orazio Flacco 65, I-70124 Bari, Italy
来源：
IMMUNOTHERAPY | 2022年 / 14卷 / 10期
关键词：
atezolizumab; breast cancer; immune checkpoint inhibitors; immunotherapy; pembrolizumab; triple-negative breast cancer; IMMUNOTHERAPY;
D O I：
10.2217/imt-2022-0021
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：755 / 758
页数：4
相关论文
共 50 条
  • [1] Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer
    van Dongen, M. G. J.
    Kok, M.
    ANNALS OF ONCOLOGY, 2020, 31 (05) : 556 - 557
  • [2] Chemoimmunotherapy for Triple-Negative Breast Cancer
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (24): : 2521 - 2521
  • [3] Chemoimmunotherapy with Pembrolizumab in triple-negative Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04)
  • [4] Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer
    Myers, Sara P.
    Sevilimedu, Varadan
    Jones, V. Morgan
    Abuhadra, Nour
    Montagna, Giacomo
    Plitas, George
    Morrow, Monica
    Downs-Canner, Stephanie M.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (08) : 5180 - 5188
  • [5] Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer
    Seager, Robert J.
    Ko, Heidi
    Pabla, Sarabjot
    Senosain, Maria-Fernanda
    Kalinski, Pawel
    Van Roey, Erik
    Gao, Shuang
    Strickland, Kyle C.
    Previs, Rebecca Ann
    Nesline, Mary K.
    Hastings, Stephanie
    Zhang, Shengle
    Conroy, Jeffrey M.
    Jensen, Taylor J.
    Eisenberg, Marcia
    Caveney, Brian
    Severson, Eric A.
    Ramkissoon, Shakti
    Gandhi, Shipra
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (05):
  • [6] Pembrolizumab in the neoadjuvant Treatment of early triple-negative Breast Cancer
    Dierks, Friederike
    Pietsch, Elisabeth
    Dunst, Juergen
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (09) : 841 - 843
  • [7] Neoadjuvant Therapy in early triple-negative Breast Cancer strengthened
    Klein, Friederike
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2025, 150 (07)
  • [8] Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
    Rizzo, Alessandro
    Cusmai, Antonio
    Massafra, Raffaella
    Bove, Samantha
    Comes, Maria Colomba
    Fanizzi, Annarita
    Rinaldi, Lucia
    Acquafredda, Silvana
    Gadaleta-Caldarola, Gennaro
    Oreste, Donato
    Zito, Alfredo
    Giotta, Francesco
    Lorusso, Vito
    Palmiotti, Gennaro
    CELLS, 2022, 11 (12)
  • [9] Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
    Rizzo, Alessandro
    Cusmai, Antonio
    Gadaleta-Caldarola, Gennaro
    Palmiotti, Gennaro
    MEDICINA-LITHUANIA, 2022, 58 (05):
  • [10] Exploring the "chemo"in chemoimmunotherapy for triple-negative breast cancer
    Liu, Ting
    Ellisen, Leif W.
    CANCER CELL, 2025, 43 (03) : 332 - 334
12345